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Abstract
Background: Familial amyloidotic polyneuropathy (FAP) is a neurodegenerative disease caused by the extracellular
deposition of mutant transthyretin (TTR), with special involvement of the peripheral nervous system (PNS). Currently,
hepatic transplantation is considered the most efficient therapy to halt the progression of clinical symptoms in FAP since
more than 95% of TTR is produced by the liver. However, less invasive and more reliable therapeutic approaches have been
proposed for FAP therapy, namely based on drugs acting as inhibitors of amyloid formation or as amyloid disruptors. We
have recently reported that epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea, is able to inhibit
TTR aggregation and fibril formation, ‘‘in vitro’’ and in a cellular system, and is also able to disrupt pre-formed amyloid fibrils
‘‘in vitro’’.
Methodology and Principal Findings: In the present study, we assessed the effect of EGCG subchronic administration on
TTR amyloidogenesis ‘‘in vivo’’, using well characterized animal models for FAP. Semiquantitative immunohistochemistry
(SQ-IHC) and Western blot analysis of mice tissues after treatment demonstrated that EGCG inhibits TTR toxic aggregates
deposition in about 50% along the gastrointestinal tract (GI) and peripheral nervous system (PNS). Moreover EGCG
treatment considerably lowered levels of several biomarkers associated with non-fibrillar TTR deposition, namely
endoplasmic reticulum (ER)-stress, protein oxidation and apoptosis markers. Treatment of old FAP mice with EGCG resulted
not only in the decrease of non-fibrillar TTR deposition but also in disaggregation of amyloid deposits. Consistently, matrix
metalloproteinase (MMP)-9 and serum amyloid P component (SAP), both markers of amyloid deposition, were also found
reduced in treated old FAP mice.
Conclusions and Significance: The dual effect of EGCG both as TTR aggregation inhibitor and amyloid fibril disruptor
together with the high tolerability and low toxicity of EGCG in humans, point towards the potential use of this compound,
or optimized derivatives, in the treatment of TTR-related amyloidoses.
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Introduction
Familial amyloidotic polyneuropathy (FAP) is an autosomal
dominant hereditary disease characterized by the extracellular
deposition of nonbranching cross b-pleated sheet fibrils in the
connective tissue, with a special involvement of the peripheral nervous
system (PNS), both autonomic and motor. The onset of clinical
symptoms generally occurs before age 40 with fast progression to death
within 10 to 20 years. Amyloid deposits are mainly composed by
transthyretin (TTR), being methionine for valine substitution at
position 30, TTR V30M, the most common molecular abnormality in
TTR [1]. More than one hundred amyloidogenic mutations have been
reported, presenting some clinical heterogeneity but typically with
peripheral nervous system (PNS) involvement [2].
Although the precise molecular mechanisms underlying TTR
fibrillogenesis have not been yet fully disclosed, it is widely
accepted that this process involves TTR tetramer dissociation,
leading to partially unfolded monomers which self-assemble
originating non-fibrillar aggregates, protofibrils and mature
amyloid fibrils [3,4]. Different TTR amyloidogenic species have
been observed ‘‘in vivo’’ as the analysis of nerve biopsy samples
from asymptomatic patients showed small non-fibrillar TTR
aggregates that in later stages of the disease coexist with amyloid
deposits [5]. Moreover, cytotoxicity of early TTR prefibrillar
aggregates, and not mature fibrils, was demonstrated by their
ability to induce oxidative and inflammatory stress in neuronal
cells, ultimately leading to cell dysfunction and death [5].
So far, the only treatment of proven efficacy for FAP is
orthotopic liver transplantation, in which the main source of
mutant TTR is eliminated. This therapeutic approach is extremely
invasive and not all patients benefit from clinical improvement [6].
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amyloidosis such as stabilization of the soluble circulating amyloid
precursor, inhibition of aggregation of amyloidogenic intermedi-
ates and disruption of insoluble deposits have been proposed [7].
Recently, our group reported that epigallocatechin-3-gallate
(EGCG), the main polyphenolic constituent of green tea, binds
to soluble TTR, increases protein resistance to dissociation, and
inhibits TTR fibril formation ‘‘in vitro’’ [8,9]. Unexpectedly,
EGCG-TTR interaction does not encompass the thyroxine (T4,a
physiological TTR ligand) binding pocket [8,10], which has been
the primary target for structure-based design of TTR kinetic
stabilizers [11]. Instead, EGCG binds at the surface of the protein
in a region involving amino acid residues at the interface of both
dimers in the molecule promoting tetramer conformational
stabilization [10]. Furthermore, it has been shown that EGCG
disrupts mature TTR preformed fibrils ‘‘in vitro’’ [8,9]. Thus,
EGCG acts not only as inhibitor of TTR amyloid formation but
also as disruptor of amyloid fibrils.
Based on these findings, we reasoned that EGCG might impair
TTR amyloid fibril formation and its associated cytotoxicity ‘‘in
vivo’’. Therefore, we decided to test the effect of subchronic
administration of EGCG ‘‘in vivo’’, using two distinct, well
established, animal models: hTTR V30M mice [12] and hTTR
V30M/HSF mice [13]. In transgenic hTTR V30M mice non-
fibrillar deposition of mutant TTR starts at six months of age, with
particular involvement of the gastrointestinal tract (GI). Initial
aggregates evolve into mature amyloid deposits normally when
mice are over 12 months of age [14]. Although this mice model
offers a useful tool for the study of FAP pathology and treatment, it
does not recapitulate whole human disease features, since the PNS
is spared. Hence, a different animal model comparable to hTTR
V30M mice but lacking the heat shock factor 1 (HSF1) has been
generated, the TTR V30M/HSF mice [13]. This animal model
resembles human pathology by presenting TTR deposition in
PNS. We herein report the results of EGCG administration ‘‘in
vivo’’ using the above referred FAP transgenic mice models.
Materials and Methods
Ethics statement
All animal experiments performed were approved by the
Portuguese General Veterinarian Board (authorization number
024976 from DGV-Portugal) and animals were kept and used
strictly in accordance with National rules and the European
Communities Council Directive (86/609/EEC), for the care and
handling of laboratory animals.
Reagents
EGCG was purchased from Cayman Chemicals (Ann Arbor,
USA). Histoclear was purchased from National Diagnostics
(Atlanta, GA, USA). Rabbit polyclonal anti-TTR was from Dako
(Carpinteria, CA, USA). Goat polyclonal anti-BiP and rabbit
polyclonal anti-Fas were from Santa Cruz (CA, USA). Rabbit
polyclonal anti-3-nitrotyrosine was from Chemicon (Temecula,
CA, USA). Rabbit polyclonal anti-matrix metalloproteinase
(MMP)-9 and rabbit polyclonal anti-BiP were from Abcam
(Cambridge, UK). Rabbit polyclonal anti-P-eIF2a was from
Biosource (CA, USA). Mouse monoclonal anti-actin was from
Sigma (St. Louis, MO, USA). Sheep polyclonal anti-serum
amyloid P component (SAP) was a kind gift from the laboratory
of Professor Pepys, Royal Free Hospital, London. The biotin-
extravidin peroxidase kit was from Sigma. Bradford protein assay
was from BioRad (CA, USA). Proteases inhibitors, Hybond-C
membranes and ECLH (enhanced chemiluminescence) were from
GE Healthcare.
Transgenic mice
Transgenic mice for human TTR V30M in a TTR null
background [12], labeled as hTTR V30M mice 4.5 months-old
(n=10) or 17 months-old (n=11) were treated with EGCG
administrated in the drinking water (100 mg/kg/day) over 6
weeks. The EGCG solution was freshly prepared every day and
protected from light. Age matched control animals were
maintained in the same conditions and given water alone (n=6
and n=8, respectively). An additional experiment used 4.5
months-old mice expressing human TTR V30M in a TTR null
background heterozygous for the heat shock transcription factor 1
(HSF1) [13] labeled hTTR V30M/HSF mice. Similarly, mice
(n=8) were treated for the same period of time with similar
EGCG dosage. Age matched mice receiving water alone were
used as controls (n=5). After the treatment period, animals were
sacrificed following anesthesia with ketamine/xylazine. Mice
tissues in particular whole gastrointestinal tract (GI), including
esophagus, stomach, colon and duodenum, as well as the dorsal
root ganglia an sciatic nerve in the case of the hTTR TTR
V30M/HSF mice, were immediately excised and frozen at 270uC
or fixed in 4% neutral buffered formalin and embedded in paraffin
for light microscopy techniques.
Isoelectric focusing (IEF) in semi-denaturing conditions
Thirty microliters of plasma from EGCG treated mice and from
controls (non-treated mice) were subjected to native electropho-
resis (PAGE). The TTR gel band was excised and applied to a
semi-denaturing (4 M urea) pH 4–6.5 gradient isoelectric focusing
(IEF) gel run for 6 h at 1200 V [15]. Proteins were stained with
Coomassie Blue. The gels were scanned and subjected to
densitometry analysis using the ImageQuant program.
Immunohistochemistry
Tissue sections (5 mm thick) were deparaffinated in histoclear
and dehydrated in a descent alcohol series. Endogenous
peroxidase activity was inhibited with 3% hydrogen peroxide/
100% methanol, and sections were blocked in 4% fetal bovine
serum and 1% bovine serum albumin in PBS. The primary
antibodies and the respective dilutions used were: rabbit polyclonal
anti-TTR (1:1000), goat polyclonal anti-BiP (1:50), rabbit
polyclonal anti-Fas (1:200), rabbit polyclonal anti-3-nitrotyrosine
(1:500), rabbit polyclonal anti-matrix metalloproteinase (MMP)-9
(1:1500), sheep polyclonal anti-serum amyloid P component (SAP)
(1:2000), which were diluted in blocking solution and incubated
overnight at 4uC. Antigen visualization was performed with the
biotin-extravidin peroxidase kit using hydrogen peroxide and
diaminobenzidine as substrate and chromogen, respectively.
Immunohistochemistry analysis was carried out independently
by two investigators unaware of the origin of the tested tissue
sections. Semi-quantitative immunohistochemical (SQ-IHC) anal-
ysis was performed using Scion Image software. This application
enables the measurement of the area occupied by pixels
corresponding to the immunohistochemical substrate’s color that
is normalized relatively to the total area. Each slide was analyzed
in five different representative areas.
Congo Red staining
The presence of amyloid deposits in tissue sections was investigated
by Congo Red (CR) staining and observation under polarized light.
Briefly, deparaffinated tissues sections were incubated for 20 min with
EGCG as Potential Drug for TTR Amyloidosis Therapy
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staining with 0.5% Congo Red in the previous solution [16]. Following
the preparationswere washed with water,stained with hematoxilin and
analyzed under polarized light. Amyloid was identified by distinctive
green birefringence.
Total protein extracts and Western blot analysis
Mice tissues (approximately 5 mg) in particular esophagus,
stomach, colon and dorsal root ganglia were homogenized on ice
in a small glass rod homogenizer in 1 mL of lysis buffer containing
5 mM EDTA, 2 mM EGTA, 20 mM MOPS, 1% Triton X-100,
1 mM PMSF and a Protease Inhibitor Mix (GE Healthcare). After
centrifugation (14,000 rpm for 30 min at 4uC) protein concentra-
tion in the supernatant was determined by the Bradford protein
assay.
Fifty mg of total protein from each tissue were separated by 15%
SDS-PAGE and transferred onto a nitrocellulose Hybond-C
membrane using a Mini Trans-Blot Cell (BioRad) system. The
primary antibodies and the respective dilutions used were: rabbit
polyclonal anti-TTR (1:1000), rabbit polyclonal anti-BiP (1:1000),
rabbit polyclonal anti-P-eIF2a (1:500) and mouse monoclonal
anti-actin (1:5000). Detection was performed with ECLH (en-
hanced chemiluminescence). Quantification of TTR, BiP or P-
eIF2a levels was performed by densitometry using the Image-
Quant 5.1 software (Molecular Dynamics). Density values were
normalized with actin expression. Results are presented as
normalized density 6 SD.
Quantification of TTR levels in mice plasma
Mice plasma TTR was quantified by Rocket Electroimmuno-
diffusion. In brief, plasma samples were diluted at a ratio of 1:10
and applied into an agarose gel containing rabbit polyclonal anti-
TTR antibody (1:150). After electrophoresis, rocket-like precipi-
tates of antigen-antibody complexes were formed along the axis of
migration being the length proportional to antigen concentration.
Statistical analyses
All data examined were expressed as mean values 6 standard
deviation (SD). Comparison between groups was made using the
Student’s t-test. A P-value of less than 0.05 was considered
statistically significant (*P,0.05; **P,0.01; ***P,0.005).
Results
EGCG decreases non-fibrillar TTR deposition and
associated biomarkers
Based in previous ‘‘in vitro’’ studies indicating that EGCG
inhibits TTR amyloid fibril formation [8,9,10] we decided to test
its effect ‘‘in vivo’’ using FAP mice models. We started by treating
Figure 1. EGCG treatment decreases TTR deposition and associated biomarkers in stomach of hTTR V30M mice. Representative
immunohistochemistry of TTR, BiP, Fas and 3-nitrotyrosine in stomach of hTTR V30M mice treated with EGCG (right panels; n=10) and age-matched
controls (left panels; n=6). Scale bar 100 mm. Histogram: quantification of immunohistochemical images is represented as percentage of occupied
area 6 SD (**P,0.01; ***P,0.005).
doi:10.1371/journal.pone.0029933.g001
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deposition [12]. EGCG was administrated orally in the drinking
water at a concentration of 100 mg/kg/day for 6 weeks period.
This treatment period was chosen according to results from pilot
assays of 4 and 6 weeks treatment. EGCG dosage was selected
based upon available ‘‘in vivo’’ reports [17], and also taking into
account both its oral acute (LD50=2170 mg/kg) and subchronic
toxicity [18].
As predicted, this dosage did not produce adverse side effects, as
no significant difference was observed in body weight, behavior or
mortality between animals treated with EGCG and age matched
untreated controls. Quantification of TTR in mice plasma from
untreated (n=6) and from EGCG treated (n=10) hTTR V30M
mice revealed no significant difference between the two groups
(356.0679.9 mg TTR/mL and 374.6638.5 mg TTR/mL, respec-
tively), demonstrating that EGCG treatment did not interfere with
TTR expression ‘‘in vivo’’ or with TTR plasma level.
To investigate the effect of EGCG treatment on TTR stability
we analyzed serum samples from treated mice and from controls
(non-treated) by isoelectric focusing (IEF) under semi-dissociating
conditions [15]. The results revealed a two fold increase of the
ratio of TTR tetramer over total TTR as calculated by
densitometry analysis of Coomassie blue stained protein (Fig. S1)
indicating an increase of serum TTR stability in vivo after
treatment with EGCG.
We next assessed the effect of EGCG on non-fibrillar TTR
deposition on different tissues by semi quantitative immunohisto-
chemical analysis (SQ-IHC). At the end of the treatment, mice
were 6 month-old and, as expected at this age, untreated mice
revealed widespread TTR staining along the gastrointestinal (GI)
tract. In contrast, EGCG treated mice presented significant
reduction of TTR load in all GI tract organs analyzed. In
stomach, the major organ of TTR deposition in hTTR V30M
mice, we detected a decrease of approximately 40% of TTR
aggregates as can be seen in the representative IHC images and
respective quantification (Fig. 1, upper panels). These results were
further corroborated by quantification of TTR in tissue lysates by
Western blot (Fig. 2A). Moreover, the highest reduction in TTR
staining was obtained in the intestine, particularly in colon (77%
decrease) (Fig. 3, upper panels) and duodenum (Fig. S2).
Then we investigated several tissue markers formerly associated
with TTR extracellular deposition [5,19,20]. Two of those are
endoplasmic reticulum (ER)-stress markers, namely ER-resident
chaperone BiP and the phosphorylated eukaryotic initiation factor
2 (P-eIF2a) typically upregulated in FAP patients [19]. The results
showed that hTTR V30M mice treated with EGCG displayed
significant decrease of BiP expression throughout the gut,
including stomach (60% decrease) and colon (65% decrease), as
can be seen in Fig. 1 and 3, respectively. In duodenum BiP ex-
pression was also significantly reduced (Fig. S2). BiP and P-eIF2a
Figure 2. EGCG treatment decreases ER-stress markers associated with TTR deposition in stomach of hTTR V30M mice.
Representative (A) anti-TTR, (B) anti-BiP and (C) anti-P-eIF2a Western blots of stomachs from TTR V30M mice treated with EGCG and non-treated
mice. Histogram: normalized TTR/b-actin, BiP/b-actin and anti-P-eIF2a/b-actin density quantifications 6SD (*P,0.05).
doi:10.1371/journal.pone.0029933.g002
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corroborated the IHC results (Fig. 2B and C, respectively).
We also investigated the levels of the apoptotic biomarker death
receptor Fas (CD95) usually increased in tissues of patients with
TTR deposition [20]. Immunostaining analysis of mice tissues
showed that treated mice presented reduced levels of Fas in the
stomach, colon (Fig. 1 and 3, respectively) and duodenum (Fig. S2).
Tissue oxidative stress was assessed by evaluation of 3-
nitrotyrosine (3-NT), a marker for protein peroxynitrite-mediated
nitration. hTTR V30M treated mice revealed significant decrease
of 3-NT immunostaining principally in colon (Fig. 3, bottom
panels) and duodenum (Fig. S2); 3-NT was also decreased in the
stomach (Fig. 1, bottom panels).
To test the effect of EGCG on TTR deposition in the PNS we
performed a similar study with hTTR V30M/HSF mice using the
same EGCG dosage and time of treatment. In accordance with
the results for hTTR V30M mice, plasma TTR levels from hTTR
V30M/HSF control mice (n=5; 363.9665.7 mg TTR/mL) did
not differ significantly from the levels of EGCG treated animals
(n=8; 348.6667.5 mg TTR/mL). SQ-IHC analysis of tissue
sections showed that EGCG treatment significantly lowered TTR
aggregates deposition in the GI tract, namely in stomach and
colon (Fig. S3A and S3B, respectively). Accordingly, a significant
reduction in BiP levels was observed along the digestive tract,
particularly in stomach and colon (Fig. S3A and S3B). These
results are in conformity with the previous data obtained for the
hTTR V30M mice. Western blot analysis against BiP of tissue
lysates further validated the IHC data (Fig. S4A).
Concerning the involvement of PNS, hTTR V30M/HSF mice
treated with EGCG had significant reduction of extracellular TTR
deposition in dorsal root ganglia (DRG) (66% decrease) as
exemplified in representative IHC pictures and in the histograms
(Fig. 4A, upper panels). A comparable effect on TTR deposition
was observed in the sciatic nerve of EGCG treated animals
(Fig. 4B). ER-stress activation was also assessed in PNS, and the
results showed that EGCG treated hTTR V30M/HSF mice
presented approximately 50% less of BiP than controls in DRG, as
evident by IHC (Fig. 4A) and Western blot (Fig. S4B). Moreover,
Fas expression and 3-NT intracellular level were found consider-
ably lowered not only in DRG from EGCG treated mice (Fig. 4A)
but also in the sciatic nerve (data not shown). These results
sustained that EGCG interferes with TTR deposition in both GI
tract and PNS.
EGCG disrupts amyloid deposits ‘‘in vivo’’
Previous ‘‘in vitro’’ results revealed that EGCG is able to disrupt
preformed amyloid fibrils [8,9]. This prompted us to investigate
the effect of EGCG in aged hTTR V30M mice (17 months-old)
presenting amyloid deposits.
Figure 3. EGCG treatment decreases TTR deposition and associated biomarkers in colon of hTTR V30M mice. Representative
immunohistochemistry of TTR, BiP, Fas and 3-nitrotyrosine in colon of hTTR V30M mice treated with EGCG (right panels; n=10) and age-matched
non-treated animals (left panels; n=6). Scale bar 100 mm. Histogram: quantification of immunohistochemical images is represented as percentage of
occupied area 6 SD (**P,0.01; ***P,0.005).
doi:10.1371/journal.pone.0029933.g003
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animals had higher levels of TTR deposition in all GI organs
analyzed as compared with untreated younger hTTR V30M mice.
Still, EGCG administration significantly reduced TTR load in
aged mice, particularly in stomach (42% decrease) (Fig. 5), and
colon (55% decrease) (data not shown).
The effect of EGCG on the biomarkers tested above for young
hTTR V30M mice were also assessed in aged mice. BiP was found
significantly lowered in the stomach (approximately 50% decrease) of
treated mice when comparing with untreated animals, as depicted by
representative IHC in Fig. 5. The IHC results were further
corroborated by Western blot analysis against BiP in stomach lysates
(Fig. 6B). Accordingly, Fas levels were considerably decreased in
EGCG treated animals, particularly in stomach and colon.
Moreover, 3-NT was also found lowered in treated mice along the
GI tract, specifically in stomach and colon (data not shown).
Figure 4. EGCG treatment decreases TTR deposition and associated biomarkers in the peripheral nervous system (PNS) of hTTR
V30M/HSF mice. (A) Representative immunohistochemistry of TTR, BiP, Fas and 3-nitrotyrosine in dorsal root ganglia of hTTR V30M/HSF treated
with EGCG for 6 weeks (right panels; n=8) and age-matched controls (left panels; n=5). Scale bar 50 mm. (B) Immunohistochemistry of TTR in sciatic
nerve of hTTR V30M treated mice (right panels; n=8) and age-matched non-treated animals (left panels; n=5). Scale bar 50 mm. Histograms:
quantification of the levels of the referred markers expressed as percentage of occupied area 6 SD (*P,0.05; **P,0.01).
doi:10.1371/journal.pone.0029933.g004
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deposition typically begins when mice are over one year of age
[14]; thus, in 17 month-old animals (at the beginning of treatment)
TTR detection by IHC refers to whole deposited TTR, both
aggregated and fibrillar forms. The mature amyloid material was
detected by Congo Red (CR) staining in stomach sections, the
primary target-organ in this particular mice model. The results
showed that 5 out of 8 (63%) untreated animals presented fibrillar
CR-positive material in stomach, whereas only 3 out of the 11
(27%) EGCG treated animals displayed CR green birefringence
under polarized light (Fig. 5). Interestingly, the last referred
animals (3 out of 11), apparently non- responder mice, showed
significantly higher levels of SAP or MMP-9 (both markers for
mature amyloid deposition) as compared to the corresponding
group final average. These results indicate that EGCG affects
TTR congophilic deposits ‘‘in vivo’’, most probably through
disaggregation.
TTR amyloid deposits are composed not only by the mutant
protein, but also by other constituents such as serum amyloid P
component (SAP) which are non-covalently associated with
amyloid fibrils, protecting the amyloid peptide from proteolytic
breakdown [21]. We assessed the presence of mouse SAP in the
stomach from EGCG treated and untreated animals. Immuno-
histochemistry results indicated that only animals presenting
TTR congophilic deposits (+/+), showed significant levels of SAP,
while mice with non-fibrillar (+/2) and without (2/2)
deposition presented lower or negligible staining. Since matrix
metalloproteinase (MMP)-9 has been found upregulated in
amyloid laden tissues in FAP [22] we also evaluated MMP-9
levels. SQ-IHC analysis revealed that MMP-9 was notably
Figure 5. EGCG treatment decreases TTR deposition and associated biomarkers in the gastrointestinal tract of old hTTR V30M
mice. Immunohistochemistry and Congo Red analysis of stomachs from aged hTTR V30M mice treated with EGCG (right panels; n=11) and aged-
matched controls (left panels; n=8). The top 3 panels represent TTR, BiP and MMP-9 immunohistochemistry. The bottom two panels are
representative Congo Red staining (white arrows pointing at CR birefringence in a non-treated mouse) and mouse SAP immunohistochemistry. Scale
bar 100 mm. Histograms: quantification of the levels of the referred markers expressed as percentage of occupied area 6 SD (*P,0.05; **P,0.01).
doi:10.1371/journal.pone.0029933.g005
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untreated mice (Fig. 5).
Discussion
There are multiple lines of compelling evidence indicating that
EGCG can be useful for the prevention and treatment of a variety
of protein misfolding diseases. Recent ‘‘in vitro’’ studies have
shown that EGCG binds to natively unfolded proteins, such as a-
synuclein (aS) and amyloid beta (Ab), and redirects polypeptides
from their standard self-assembly cascades into small off-pathway
aggregates that are non-toxic to mammalian cells [23]. Regarding
TTR-related amyloidosis, it has also been demonstrated, ‘‘in
vitro’’ and ‘‘ex vivo’’, that EGCG binds to TTR and increases its
tetramer conformational stability. In addition, EGCG inhibits
TTR aggregation ‘‘in vitro’’ and in a cell culture system [8,9].
These findings, together with the pharmacokinetics [24] and
favorable toxicological profile in mice [18], encouraged us to
investigate the effect of subchronic administration of EGCG ‘‘in
vivo’’, using well established FAP mice models at different stages of
TTR deposition. Data available on the pharmacokinetics
indicated that a single dose intra-gastric administration of EGCG
(75 mg/Kg) originates a peak plasma level of EGCG of
0.2860.08 mmol/L and that when this administration was
repeated after 6 h interval the levels of EGCG in blood were
increased about 5.9 times and in tissues the levels were even higher
[24,25] . Since we used a superior dose of EGCG (100 mg/Kg)
and a chronic administration, we expected that the levels of
EGCG in plasma reached a plateau of concentration sufficient to
substantially stabilize plasma TTR as we really found by IEF
analysis of plasma TTR after mice treatment.
Most important, in this study, we demonstrate that EGCG
lowers TTR systemic deposition in FAP mice, particularly in the
gastrointestinal tract and peripheral nervous system. Consequent-
ly, associated biomarkers such as BiP, P-eIF2a, Fas and 3-
nitrotyrosine were also reduced along the gastrointestinal tract of
hTTR V30M and hTTR V30M/HSF and dorsal root ganglia of
hTTR V30M/HSF mice.
As pointed out by several authors, the EGCG inhibitory effect
on the amyloid formation cascade is not limited to early
intermediates of fibrillogenesis, since EGCG is also able to
efficiently remodel mature fibrils made from a variety of
amyloidogenic proteins into smaller, non-toxic unstructured
protein aggregates [8,9,26].
We also observed that EGCG displays amyloid disruptor
activity ‘‘in vivo’’ in treated aged hTTR V30M mice, that
simultaneously present non-fibrillar and fibrillar TTR forms, and
found that EGCG treatment not only lowered systemic TTR load
and associated biomarkers, but also disaggregated amyloid
deposits as evidenced by Congo Red birefringence analysis of
stomach sections (Fig. 5). It could be argued that TTR aggregates
remodeling hide antibody reactivity, however TTR reduction
under denaturing conditions in Western blots is also observed
(Fig. 6A).
These results were further supported by substantial decrease of
matrix metalloproteinase (MMP)-9 levels in EGCG treated mice,
Figure 6. EGCG treatment decreases TTR amyloid deposition in the gastrointestinal tract of old hTTR V30M mice. Representative (A)
anti-TTR and (B) anti-BiP Western blots of stomachs from aged hTTR V30M mice treated with EGCG and non-treated mice. Histogram: normalized
TTR/b-actin and BiP/b-actin density quantifications 6SD (*P,0.05).
doi:10.1371/journal.pone.0029933.g006
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inflammation reduction and matrix recovery. Nevertheless, several
reports indicate EGCG as an inhibitor of MMP-9 expression [27],
thus we cannot fully determine whether the significant MMP-9
reduction in treated animals was only due to EGCG-mediated
TTR amyloid disaggregation or, in some extension, by direct
action of EGCG on MMP-9 transcriptional activity. However,
since serum amyloid P component (SAP) is a universal marker of
amyloid its reduction points towards a direct effect of EGCG on
TTR amyloid removal.
Though liver transplantation is the most efficient therapy
available for FAP many patients present progression of the disease
after hepatic transplantation and the procedure is not suitable for
the treatment of a large number of patients. Hence, alternative
therapeutic approaches including small TTR stabilizers
[11,28,29], fibril disruptors [30], modulators of aggregate-induced
toxicity [31,32] or combined drug therapy [33] have been
proposed. However, adverse side effects such as heart, liver or
gastrointestinal dysfunction are associated with the use of some of
these drugs ‘‘in vivo’’, a major disadvantage when considering
experimental research in FAP patients.
EGCG is the most abundant catechin in green tea and it has
been widely recognized has safe in humans [34]. In addition, a
recent study [35] on the green tea flavan-3-ols pharmacokinetics in
humans revealed that their calculated bioavailability was approx-
imately 39% and that EGCG was the only unmetabolized
compound and the highest in absolute concentration. These
findings might support previous reports indicating clinical benefit
from green tea consumption (1.5–2 L/daily, equivalent of 600–
800 mg EGCG) in patients with amyloid light chain (AL)
amyloidosis [36,37]. Very recently, Mereles and Hunstein [38]
described several factors that may contribute to the increase of
bioavailability of EGCG such as the concomitant ingestion of
vitamin C, fish oil and piperine that should be taken into account
when considering EGCG oral administration. Hence, only
upcoming studies on chronic EGCG dietary supplementation in
humans will further elucidate its plasma pharmacokinetics and
tissue distribution.
Although EGCG may be used in different stages of disease
progression we postulate that its potential therapeutic administra-
tionshould preferentially address early phases of FAP since: (i) tissue
deposition of small toxic TTR aggregates occurs at asymptomatic
stage [14] (ii) EGCG inhibitory effect on TTR aggregation and
associated cytotoxicity was more pronounced in younger FAP mice
(iii) multiple organ dysfunction caused by space-occupying amyloid
deposits may be clinically difficult to reverse.
Most of the TTR-related amyloidosis does not affect the central
nervous system (CNS) but there are few TTR mutations (about 10
variants) associated with TTR amyloid deposition in the
leptomeninges [39]. Therefore, EGCG ability to cross the blood-
brain barrier [24] might be particularly suitable for those cases. It
is well proven that tea catechins, in particular EGCG, possess free
radical scavenging properties and act as biological antioxidants
[40]. Moreover, EGCG can chelate metal ions, such as iron (III),
to produce inactive complexes preventing metal-induced lipid
peroxidation [41]. Thus, we do not disregard that together with its
ability to directly modulate TTR fibrillogenesis, EGCG antioxidant
and iron chelating activities may potentiate a neuroprotective effect
‘‘in vivo’’. Hence, we propose EGCG, or optimized derivatives, as
drug candidates for the treatment of FAP and amyloid diseases in
general, paving the way for future clinical trials.
Supporting Information
Figure S1 EGCG treatment increases plasma TTR resis-
tance to dissociation. (A) Plasmas from 6 month-old hTTR V30M
mice treated with EGCG (n=10) and non-treated mice (n=6) were
subjected to isoelectric focusing analysis (IEF) under semi-denaturing
conditions (4 M urea). These conditions allow the visualization of
different molecular species corresponding to TTR monomers, an
oxidized form of the monomer and tetramers. (B) The histogram
shows TTR tetramer/total TTR bands ratio obtained after densi-
tometry analysis of IEF gels) (**P,0.01).
(TIF)
Figure S2 EGCG treatment decreases TTR deposition
and associated biomarkers in duodenum of hTTR V30M
mice. Representative immunohistochemical analysis of TTR,
BiP, Fas and 3-NT in duodenum of hTTR V30M mice treated
with EGCG (right panels; n=10) and age-matched controls (left
panels; n=6). Scale bar 100 mm. Histogram: quantification of
immunohistochemical images is represented as percentage of
occupied area 6 SD (**P,0.01; ***P,0.005).
(TIF)
Figure S3 EGCG treatment decreases TTR deposition
and ER-stress marker BiP in the gastrointestinal tract of
hTTR V30M/HSF mice. (A) Immunohistochemistry of TTR
(upper panels) and BiP (lower panels) in stomach of hTTR V30M/
HSF mice treated with EGCG (right panels; n=8) and age-
matched controls (left panels; n=5). Scale bar 100 mm. (B)
Immunohistochemistry of TTR (upper panels) and BiP (lower
panels) in colon of hTTR V30M mice/HSF treated with EGCG
(right panels; n=8) and controls (left panels; n=5). Scale bar
100 mm. Histograms: quantification of immunohistochemical
images is represented as percentage of occupied area 6 SD
(**P,0.01; ***P,0.005).
(TIF)
Figure S4 EGCG treatment decreases ER-stress marker
BiP in stomach and dorsal root ganglia of hTTR V30M/
HSF mice. Anti-BiP Western blot analysis of protein extracts
from (A) stomachs and (B) dorsal root ganglia of hTTR V30M/
HSF mice treated with EGCG and non-treated mice. Histogram:
normalized BiP/b-actin density quantifications 6SD (*P,0.05).
(TIF)
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